CALGARY, Alberta--(BUSINESS WIRE)--Absorb Software, maker of Absorb Learning Management System (LMS) has successfully completed its AICPA System and Organization Controls (SOC) 2 Type 2 examination ...
At 2 years, there are no significant differences with regard to clinical outcomes between the Absorb everolimus-eluting bioresorbable scaffold and the Xience everolimus-eluting stent, according to ...
AMSTERDAM, NL — Consistent with prior trials, the risk of scaffold thrombosis was significantly higher in patients receiving the Absorb (Abbott Vascular) bioresorbable vascular scaffold (BVS) than an ...
- Trial to Study the Innovative "Dissolving" Heart Device Compared to Abbott's Market-Leading Drug Eluting Stents in Patients with Coronary Artery Disease in Japan The Absorb BVS, a drug eluting, ...
Please provide your email address to receive an email when new articles are posted on . WASHINGTON — The Absorb bioresorbable scaffold demonstrated overall clinical outcomes comparable to those of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results